Search - tctmd.com

Displaying 41 - 53 of 53

Sort: Relevancy | Date

News Industry News

Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013

May 17, 2013

News Industry News

New Four-Year Data From Boston Scientific Demonstrated WATCHMAN® Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The P

May 09, 2013

News Industry News

World’s First Pulmonary Embolism Trial Comparing Endovascular Therapy to Standard of Care

March 08, 2013

News Industry News

Boston Scientific Demonstrates Ongoing Structural Heart Advances at Transcatheter Cardiovascular Therapeutics 2012 in Miami

October 23, 2012

News Industry News

FDA expands approved use of Sapien artificial heart valve

October 19, 2012

News Industry News

Key Clinical Data for St. Jude Medical’s Structural Heart Technologies Revealed at EuroPCR

May 16, 2012

News Industry News

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

May 11, 2012

News Industry News

Boston Scientific's WATCHMAN® Device Implanted in First Patients in Latin America

November 15, 2011

News Industry News

First Research Results of Angiomax(R) (Bivalirudin) Versus Heparin in Transcatheter Aortic Valve Interventions Reported at TCT

November 07, 2011

News Industry News

Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System

November 06, 2011

News Industry News

FDA approves first artificial aortic heart valve placed without open-heart surgery

November 02, 2011

News Industry News

On-X Heart Valve PROACT Trial Preliminary Report Provides Evidence Toward Maintaining Patients With Less Warfarin

April 05, 2011

News Industry News

Boston Scientific to Acquire Atritech

January 18, 2011

Advertisement

Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013

New Four-Year Data From Boston Scientific Demonstrated WATCHMAN® Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The P

World’s First Pulmonary Embolism Trial Comparing Endovascular Therapy to Standard of Care

Boston Scientific Demonstrates Ongoing Structural Heart Advances at Transcatheter Cardiovascular Therapeutics 2012 in Miami

FDA expands approved use of Sapien artificial heart valve

Key Clinical Data for St. Jude Medical’s Structural Heart Technologies Revealed at EuroPCR

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

Boston Scientific's WATCHMAN® Device Implanted in First Patients in Latin America

First Research Results of Angiomax(R) (Bivalirudin) Versus Heparin in Transcatheter Aortic Valve Interventions Reported at TCT

Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System

FDA approves first artificial aortic heart valve placed without open-heart surgery

On-X Heart Valve PROACT Trial Preliminary Report Provides Evidence Toward Maintaining Patients With Less Warfarin

Boston Scientific to Acquire Atritech

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content